Adjunct therapy to reduce iatrogenic hyperinsulinemia in T1D
What this study tests
Mechanistic crossover study comparing insulin exposure and tissue glucose disposal and nitric-oxide availability. It includes T1D, GCK-MODY and control cohorts; it is not an established adjunct-treatment efficacy trial.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2025-12-23.
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Ages 18–60, BMI18–28 and weight at least 50 kg. The T1D cohort requires 1–30 years duration, AID use and HbA1c 5.7–7.5%; GCK-MODY and control cohorts have different requirements. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted yet.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: United States. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Aim 1: Tissue glucose disposal (TGD)
- Aim 2: Nitric Oxide (NO) bioavailability
The full picture
This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.
Sources
- [1]